Verified peer comparison

ZTS vs MRK

Zoetis Inc. compared with Merck & Co., Inc.. This page compares both source-verified company profiles and does not introduce an unverified price target.

ZTS

Zoetis Inc.

$189.43

Open: --
High: --
Low: --
Market Cap: --

Open stock research

MRK

Merck & Co., Inc.

$189.43

Open: --
High: --
Low: --
Market Cap: --

Open stock research

Company-specific comparison

Business exposure

ZTS: Pharmaceuticals

MRK: Pharmaceuticals

Upside lens

ZTS: Pet owners' focus on longevity and quality of life can sustain medicines, vaccines and diagnostics demand. Librela and Solensia can expand treatment of chronic pain in dogs and cats as veterinarian familiarity grows. New vaccines, diagnostics and monoclonal antibodies can extend a differentiated portfolio.

MRK: Continued oncology demand and new indications can sustain growth while Merck expands the franchise beyond its established uses. Increasing contributions from newer medicines across cardiometabolic, respiratory, and HIV markets can diversify growth beyond the largest established products. A robust period of Phase 3 readouts and regulatory milestones could validate Merck's efforts to build a broader set of future growth drivers.

Risk lens

ZTS: Adverse-event concerns or label changes could slow adoption of important companion-animal products. Clinic staffing constraints and affordability pressure can limit visits, diagnoses and treatment starts. Disease outbreaks, commodity economics and regulation can cause abrupt changes in producer demand.

MRK: Merck remains highly dependent on Keytruda, making future patent expiry, competition, and the pace of portfolio diversification material risks. Declines in vaccines, including demand pressure affecting Gardasil, can offset gains in oncology and newer launches. Large acquisition-related charges and continuing development investment can create earnings volatility before acquired pipeline assets generate returns.